US Patent

US10610489 — Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof

Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2030-09-30 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical compositions that combine a SGLT-2 inhibitor drug with a partner drug.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Drugs covered by this patent

Patent Metadata

Patent number
US10610489
Jurisdiction
US
Classification
Formulation
Expires
2030-09-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.